Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease
Positive
AI Analysis
Summary
Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals for $4.1 billion USD in a definitive agreement, expanding Angelini's presence in the U.S. market and strengthening its portfolio in brain health and rare diseases.
Outcome Details
Definitive agreement entered for acquisition at $4.1 billion USD ($3.5 billion Euros)
Importance:8/10
Sentiment:
0.70
M&Aacquisitionbrain healthrare diseasemarket entry
Related Companies
Read the original article
Published by GlobeNewswire Pharma on May 7, 2026 7:25 AM